AstraZeneca Casodex FDA Cmte. To Focus On Efficacy Differences In Trials

AstraZeneca expects FDA's Oncologic Drugs Advisory Committee's Casodex review to focus on the apparent lower efficacy of the prostate cancer drug in U.S. trials compared to those outside the U.S